132 related articles for article (PubMed ID: 31913208)
1. A Case of Response to Immunotherapy in a Patient With MSI Metastatic Colorectal Cancer and Autoimmune Disease Receiving Steroid Therapy.
Massucci M; Di Fabio F; Rojas Llimpe FL; Ardizzoni A
J Immunother; 2020 Jun; 43(5):153-155. PubMed ID: 31913208
[TBL] [Abstract][Full Text] [Related]
2. Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer.
Morse MA; Overman MJ; Hartman L; Khoukaz T; Brutcher E; Lenz HJ; Atasoy A; Shangguan T; Zhao H; El-Rayes B
Oncologist; 2019 Nov; 24(11):1453-1461. PubMed ID: 31147488
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab for the treatment of colorectal cancer.
Smith KM; Desai J
Expert Rev Anticancer Ther; 2018 Jul; 18(7):611-618. PubMed ID: 29792730
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer.
Mehrvarz Sarshekeh A; Overman MJ; Kopetz S
Future Oncol; 2018 Aug; 14(18):1869-1874. PubMed ID: 29473436
[TBL] [Abstract][Full Text] [Related]
5. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
[TBL] [Abstract][Full Text] [Related]
6. Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management.
Overman MJ; Ernstoff MS; Morse MA
Am Soc Clin Oncol Educ Book; 2018 May; 38():239-247. PubMed ID: 30231358
[TBL] [Abstract][Full Text] [Related]
7. PD-1 Blockade in a Liver Transplant Recipient With Microsatellite Unstable Metastatic Colorectal Cancer and Hepatic Impairment.
Chen JA; Esteghamat N; Kim EJ; Garcia G; Gong J; Fakih MG; Bold RJ; Cho MT
J Natl Compr Canc Netw; 2019 Sep; 17(9):1026-1030. PubMed ID: 31487676
[TBL] [Abstract][Full Text] [Related]
8. Immunopathologic Stratification of Colorectal Cancer for Checkpoint Blockade Immunotherapy.
Llosa NJ; Luber B; Siegel N; Awan AH; Oke T; Zhu Q; Bartlett BR; Aulakh LK; Thompson ED; Jaffee EM; Durham JN; Sears CL; Le DT; Diaz LA; Pardoll DM; Wang H; Housseau F; Anders RA
Cancer Immunol Res; 2019 Oct; 7(10):1574-1579. PubMed ID: 31439614
[TBL] [Abstract][Full Text] [Related]
9. An update on the use of immunotherapy in patients with colorectal cancer.
Nguyen M; Tipping Smith S; Lam M; Liow E; Davies A; Prenen H; Segelov E
Expert Rev Gastroenterol Hepatol; 2021 Mar; 15(3):291-304. PubMed ID: 33138649
[No Abstract] [Full Text] [Related]
10. Mismatch repair deficient metastatic colon cancer and urothelial cancer: A case report of sequential immune checkpoint therapy.
Ghatalia P; Nagarathinam R; Cooper H; Geynisman DM; El-Deiry WS
Cancer Biol Ther; 2017 Sep; 18(9):651-654. PubMed ID: 28726535
[TBL] [Abstract][Full Text] [Related]
11. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164.
Le DT; Kim TW; Van Cutsem E; Geva R; Jäger D; Hara H; Burge M; O'Neil B; Kavan P; Yoshino T; Guimbaud R; Taniguchi H; Elez E; Al-Batran SE; Boland PM; Crocenzi T; Atreya CE; Cui Y; Dai T; Marinello P; Diaz LA; André T
J Clin Oncol; 2020 Jan; 38(1):11-19. PubMed ID: 31725351
[TBL] [Abstract][Full Text] [Related]
12. Clinical responses to PD-1 inhibition and their molecular characterization in six patients with mismatch repair-deficient metastatic cancer of the digestive system.
Hirsch D; Gaiser T; Merx K; Weingaertner S; Forster M; Hendricks A; Woenckhaus M; Schubert T; Hofheinz RD; Gencer D
J Cancer Res Clin Oncol; 2021 Jan; 147(1):263-273. PubMed ID: 32776177
[TBL] [Abstract][Full Text] [Related]
13. Current status and perspectives of immune checkpoint inhibitors for colorectal cancer.
Hirano H; Takashima A; Hamaguchi T; Shida D; Kanemitsu Y;
Jpn J Clin Oncol; 2021 Jan; 51(1):10-19. PubMed ID: 33205813
[TBL] [Abstract][Full Text] [Related]
14. Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status.
Loupakis F; Maddalena G; Depetris I; Murgioni S; Bergamo F; Dei Tos AP; Rugge M; Munari G; Nguyen A; Szeto C; Zagonel V; Lonardi S; Fassan M
J Immunother Cancer; 2019 Nov; 7(1):297. PubMed ID: 31703605
[TBL] [Abstract][Full Text] [Related]
15. AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
Antoniotti C; Borelli B; Rossini D; Pietrantonio F; Morano F; Salvatore L; Lonardi S; Marmorino F; Tamberi S; Corallo S; Tortora G; Bergamo F; Brunella DS; Boccaccino A; Grassi E; Racca P; Tamburini E; Aprile G; Moretto R; Boni L; Falcone A; Cremolini C
BMC Cancer; 2020 Jul; 20(1):683. PubMed ID: 32698790
[TBL] [Abstract][Full Text] [Related]
16. Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer.
Thomas J; Leal A; Overman MJ
Clin Colorectal Cancer; 2020 Jun; 19(2):73-81. PubMed ID: 32173280
[TBL] [Abstract][Full Text] [Related]
17. Integrating Immunotherapy Into Colorectal Cancer Care.
Wilt C; Le DT
Oncology (Williston Park); 2018 Oct; 32(10):494-8. PubMed ID: 30334238
[TBL] [Abstract][Full Text] [Related]
18. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
19. The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma.
Almquist DR; Ahn DH; Bekaii-Saab TS
BioDrugs; 2020 Jun; 34(3):349-362. PubMed ID: 32246441
[TBL] [Abstract][Full Text] [Related]
20. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
